These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270 [TBL] [Abstract][Full Text] [Related]
3. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575 [TBL] [Abstract][Full Text] [Related]
4. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. Ksienski D; Wai ES; Croteau NS; Freeman AT; Chan A; Fiorino L; Poonja Z; Fenton D; Patterson T; Irons S; Lesperance M J Geriatr Oncol; 2020 Jun; 11(5):807-813. PubMed ID: 31937494 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J; Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994 [TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301 [TBL] [Abstract][Full Text] [Related]
9. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab. Friedlaender A; Metro G; Signorelli D; Gili A; Economopoulou P; Roila F; Banna G; De Toma A; Camerini A; Christopoulou A; Lo Russo G; Banini M; Galetta D; Jimenez B; Collazo-Lorduy A; Calles A; Baxevanos P; Linardou H; Kosmidis P; Mountzios G; Garassino MC; Addeo A Acta Oncol; 2020 Sep; 59(9):1058-1063. PubMed ID: 32762415 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424 [No Abstract] [Full Text] [Related]
11. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival. Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. Ksienski D; Wai ES; Alex D; Croteau NS; Freeman AT; Chan A; Patterson T; Clarkson M; Fiorino L; Poonja Z; Fenton D; Irons S; Lesperance M Transl Lung Cancer Res; 2021 Jan; 10(1):355-367. PubMed ID: 33569318 [TBL] [Abstract][Full Text] [Related]
13. Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias. Ishidoya M; Makiguchi T; Tanaka H; Miura T; Nunomura Y; Miura D; Morimoto T; Hasegawa Y; Taima K; Tasaka S Lung Cancer; 2024 Jun; 192():107790. PubMed ID: 38696920 [TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50. Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Santoni M; Tudini M; Rijavec E; Filetti M; Catino A; Pizzutilo P; Sala L; Citarella F; Marco R; Torniai M; Cantini L; Targato G; Sforza V; Nigro O; Ferrara MG; D'Argento E; Buti S; Bordi P; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Della Gravara L; Dal Bello MG; Belderbos RA; Bironzo P; Carnio S; Ricciardi S; Grieco A; De Toma A; Proto C; Friedlaender A; Cantale O; Ricciuti B; Addeo A; Metro G; Ficorella C; Porzio G Cancer Immunol Immunother; 2020 Nov; 69(11):2209-2221. PubMed ID: 32474768 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661 [TBL] [Abstract][Full Text] [Related]
17. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704 [TBL] [Abstract][Full Text] [Related]
18. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659 [TBL] [Abstract][Full Text] [Related]
19. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Felip E; Goldman JW; Scalzo C; Jensen E; Kush DA; Hui R J Clin Oncol; 2019 Oct; 37(28):2518-2527. PubMed ID: 31154919 [TBL] [Abstract][Full Text] [Related]
20. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status. Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]